Pros | - | ![]() Among most bought funds within the category. ![]() Larger AUM within category. ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | - |
INDMoney rank | - | 5/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 1 Years | 12 Years | ||
Fund Size | 332 Cr | 8352 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹500 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.68% | 0.89% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 48 | 40 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (8.76%) Divi's Laboratories Ltd (7.76%) Max Healthcare Institute Ltd Ordinary Shares (7.52%) Cipla Ltd (5.66%) Fortis Healthcare Ltd (5.12%) | Sun Pharmaceuticals Industries Ltd (12.57%) Divi's Laboratories Ltd (9.49%) Lupin Ltd (5.82%) Cipla Ltd (5.62%) Dr Reddy's Laboratories Ltd (5.49%) | ||
No of Sectors | 4 | 1 | ||
Top 3 Sectors | Health (94.77%) Government (34.63%) Basic Materials (4.49%) | Health (100%) | ||
Equity % | 93.87% | 98.58% | ||
Debt % | - | - | ||
P/E | 42.39 | 36.85 | ||
P/B | 7.15 | 5.96 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 4.42% | 3% | ||
3-Month Return | 6.71% | 8.07% | ||
6-Month Return | -0.49% | -1.11% | ||
1-Year Return | 30.53% | 17.39% | ||
3-Year Return | - | 26.91% | ||
5-Year Return | - | 23.54% |
Sharpe | - | 1.13 | ||
Alpha | - | 1.66 | ||
Beta | - | 0.9 | ||
Standard Deviation | - | 14.97 | ||
Information Ratio | - | 0.02 |
Description | WhiteOak Capital Pharma and Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Piyush Baranwal | Sailesh Raj Bhan,Kinjal Desai |